Literature DB >> 23463127

Dose-dependent relapse of hiatus hernia after administration of intrathecal baclofen treatment--a rare complication.

Peter Weber1.   

Abstract

INTRODUCTION: Intrathecal baclofen treatment (ITB) is widely used in children with cerebral palsy. Although this treatment effectively reduces spasticity, diverse side effects are reported. CASE REPORT: We report about a boy with severe asphyxia-induced encephalopathy with bilateral cerebral palsy. After starting the intrathecal baclofen treatment, he episodically showed symptoms of severe gastroesophageal reflux with pale skin color, vomiting, massive drooling, acid regurgitation, and reduced well-being. An open ventral semifundoplication was done some years ago to treat a gastroesophageal reflux. These symptomatic episodes occurred strongly dose-dependent and were not observed during the short test procedure.
CONCLUSION: For the first time, a strong dose-dependent treatment with ITB was documented as a cause for the above episodes and relapsing re-herniations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23463127     DOI: 10.1007/s00381-013-2058-z

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  15 in total

1.  Recurrent gastroesophageal reflux in neurologically impaired patients after fundoplication.

Authors:  A Goessler; A Huber-Zeyringer; M E Hoellwarth
Journal:  Acta Paediatr       Date:  2007-01       Impact factor: 2.299

2.  Baclofen, a treatment for chronic hiccup.

Authors:  P Walker; S Watanabe; E Bruera
Journal:  J Pain Symptom Manage       Date:  1998-08       Impact factor: 3.612

3.  Progression of scoliosis in patients with spastic quadriplegia after the insertion of an intrathecal baclofen pump.

Authors:  Glen M Ginsburg; Anthony J Lauder
Journal:  Spine (Phila Pa 1976)       Date:  2007-11-15       Impact factor: 3.468

4.  Safety and one-year efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy.

Authors:  Marjanke A Hoving; Elisabeth P M van Raak; Geert H J J Spincemaille; Vivianne H J M van Kranen-Mastenbroek; Maarten van Kleef; Jan Willem Gorter; Johan S H Vles
Journal:  Eur J Paediatr Neurol       Date:  2008-06-30       Impact factor: 3.140

5.  The impact of intrathecal baclofen on the natural history of scoliosis in cerebral palsy.

Authors:  Jeffrey S Shilt; Lawrence P Lai; Michael N Cabrera; John Frino; Beth P Smith
Journal:  J Pediatr Orthop       Date:  2008-09       Impact factor: 2.324

Review 6.  Gastrointestinal disorders in children with neurodevelopmental disabilities.

Authors:  Peter B Sullivan
Journal:  Dev Disabil Res Rev       Date:  2008

7.  Experience with external pump trial prior to implantation for intrathecal baclofen in ambulatory patients with spastic cerebral palsy.

Authors:  C Bleyenheuft; P Filipetti; C Caldas; T Lejeune
Journal:  Neurophysiol Clin       Date:  2007-02-08       Impact factor: 3.734

8.  Complications of intrathecal baclofen pump therapy in pediatric patients.

Authors:  Andrzej Borowski; Aaron G Littleton; Battugs Borkhuu; Ana Presedo; Suken Shah; Kirk W Dabney; Sharon Lyons; Maura McMannus; Freeman Miller
Journal:  J Pediatr Orthop       Date:  2010 Jan-Feb       Impact factor: 2.324

Review 9.  Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  M R Delgado; D Hirtz; M Aisen; S Ashwal; D L Fehlings; J McLaughlin; L A Morrison; M W Shrader; A Tilton; J Vargus-Adams
Journal:  Neurology       Date:  2010-01-26       Impact factor: 9.910

10.  Risk factors for recurrent gastroesophageal reflux disease after fundoplication in pediatric patients: a case-control study.

Authors:  Monawat Ngerncham; Douglas C Barnhart; Ramanath N Haricharan; Jeffrey M Roseman; Keith E Georgeson; Carroll M Harmon
Journal:  J Pediatr Surg       Date:  2007-09       Impact factor: 2.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.